Saturday 17 October 2026
Export NDRA’s income statement to Excel — free account
ENDRA Life Sciences Inc.
NDRA Healthcare Diagnostics & Research
In the quarter to June 2026, EPS grew 107.0% and free cash flow grew 15.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.74
0.36
−7.06%
Follow NDRA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(236.34%) | (291.56%) | (412.59%) | (152.04%) | |
| (154.83%) | (169.21%) | (220.99%) | (110.08%) | ||
ROIC |
0.00% | (240.50%) | (282.59%) | (539.89%) | |
Return on Tangible Assets |
(2,660.20%) | (2,708.05%) | 2,748.40% | (122.15%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(6.71) | (10.42) | (4.17) | (5.92) | |
Free Cash Flow |
(5.10) | (8.20) | (5.01) | (7.84) | |
Capital Expenditures |
(0.02) | (3.02) | — | (3.02) | |
| Other line items | |||||
Cash ROIC |
(528.67%) | (271.30%) | (233.70%) | (66.18%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.64 | 0.74 | 0.69 | 0.82 | |
Depreciation/Fixed assets |
3.12 | 3.70 | 4.59 | 3.63 | |
Capex/Depreciation |
(0.11) | (19.18) | 0.00 | (19.13) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.68) | (6.59) | (4.17) | (3.64) | |
Capex per Share |
(0.02) | (3.83) | 0.00 | (2.28) | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates